Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

Not Applicable

Terminated

• Conditions: Metastatic Prostate Carcinoma
• Interventions: Other: FLT PET/CT

• Registration Number: NCT03011749
• Lead Sponsor: Rigshospitalet, Denmark

Brief Summary

The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01
• Study First Submitted: 2017-01-04
• Study First Submitted QC: 2017-01-04
• Study First Posted: 2017-01-05
• Primary Completion: 2018-02
• Study Completion: 2018-02
• Status Verified: 2019-09
• Last Update Submitted: 2019-09-10
• Last Update Posted: 2019-09-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Male
• Target Recruitment: 6

Inclusion Criteria

• Metastatic castration resistant prostate cancer
• Eligible for Radium-223 therapy
• Informed consent

Exclusion Criteria

• Inability to understand study protocol
• Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
FLT PET/CT	FLT PET/CT	FLT PET/CT

Primary Outcome Measures

Name	Time	Method
Uptake of FLT in hematological bone marrow	3 months

Secondary Outcome Measures

Name	Time	Method
Occurrence of hematological toxicity	12 months

Trial Locations

Locations (1)

Rigshospitalet; 🇩🇰 Copenhagen, Denmark